.gen Technologies Inc.

A spectacular result for local biotech Isis Pharmaceuticals with their cholesterol candidate mipomercen. This trial saw an average 25% reduction in LDL for genetically suseptible patients, with some seeing reductions of 70 – 80%. That’s great news for Isis and marketing partner Genzyme.

http://www.fiercebiotech.com/story/isis-cholesterol-drug-hits-bulls-eye-pivotal-trial/2009-11-17?utm_medium=nl&utm_source=internal

We are just back from the NIH’s mHealth Summit, where we learned about cutting edge innovations in mobile healthcare from the West, Latin America and Africa. Contact us to find out more about what we learned, and how it might apply to your organization.